Po-Jung Su

Po-Jung Su
EDUCATION: 1997-2004 China Medical University, Tai-Chung, Taiwan 2016-2018 Graduate institute of data science, master degree, Taipei Medical University, Taiwan RESEARCH AND PROFESSIONAL EXPERIENCE: 2006-2009 Resident in Department of Internal Medicine, Chang Gung Memorial Hospital (CGMH), Taipei, Taiwan 2009-2011 Clinical Fellow in Division of Medical Oncology, Department of Internal Medicine, CGMH 2013-2015 Attending Physician in Medical Oncology, Xiamen CGMH, China Executive secretary of oncology committee, Xiamen CGMH, China Leader of anti-cancer treatment quality control team, Xiamen CGMH, China 2011-present Attending Physician in Medical Oncology, CGMH Member of genitourinary cancer team, Linkou CGMH, Taiwan Member of hospice care committee, Linkou CGMH, Taiwan AFFILIATIONS: Taiwan Medical Association Society of Internal Medicine, Republic of China. Society of Chinese Oncology Taiwan Urological Oncology Association Taiwan Association of Cancer Research

16th August 2025

Time Session
13:30
15:00
Industry Symposium 10 【Astellas】
Recent Advancements in Muscle-Invasive Urothelial Carcinoma
  • Welcome
    Wayne Yen-Hwa ChangTaiwan Moderator
  • Recent Advancements in Muscle-Invasive Urothelial Carcimoma
    Cheng-Kuang YangTaiwan Speaker Robotic Radical Prostatectomy: Trying to Fit the Right Surgery to the Right PatientDefinitive treatment for localized prostate cancer included radical prostatectomy and radiation. Successful criteria of radical prostatectomy have to meet oncology control, not persistent PSA after surgery without salvage therapy. MRI imaging stage and PSA density are predictors for short‐term BCR after prostatectomy. NCCN‐defined high‐risk patients with a high initial PSA 28 density, imaging stage (T3aN0M0 and T3bN0M0), and 29 pathologic stage (any N1) had a higher risk of BCR when 30 compared with other patients with undetectable PSA, while 31 those with pathologic stage (T3bN0M0 or any N1) displayed 32 a higher risk of postoperatively detectable PSA. These find‐ 33 ings may help urologists to identify patients for whom active 34 therapeutic protocols are necessary.
  • Panel Discussion - Can We Adapt the Treatment Paradigm Shift in Early Stage UC?
    Wayne Yen-Hwa ChangTaiwan Moderator
    Cheng-Kuang YangTaiwan Speaker Robotic Radical Prostatectomy: Trying to Fit the Right Surgery to the Right PatientDefinitive treatment for localized prostate cancer included radical prostatectomy and radiation. Successful criteria of radical prostatectomy have to meet oncology control, not persistent PSA after surgery without salvage therapy. MRI imaging stage and PSA density are predictors for short‐term BCR after prostatectomy. NCCN‐defined high‐risk patients with a high initial PSA 28 density, imaging stage (T3aN0M0 and T3bN0M0), and 29 pathologic stage (any N1) had a higher risk of BCR when 30 compared with other patients with undetectable PSA, while 31 those with pathologic stage (T3bN0M0 or any N1) displayed 32 a higher risk of postoperatively detectable PSA. These find‐ 33 ings may help urologists to identify patients for whom active 34 therapeutic protocols are necessary.
    Po-Jung SuTaiwan Speaker
    Yu-Chieh TsaiTaiwan Speaker
  • Closing
TICC - 1F 101C